Morphologic changes induced by neoadjuvant combination hormone therapy on prostatic tissue and prostate cancer

Endocrine-Related Cancer

Volumn 3, Issue 3, 1996, Pages 165-170

  Tetu B ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029959855     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030165     Document Type: Article

References (20)

1. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR & Reuter V 1994 Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. American Journal of Surgical Pathology 18 979-991.
2. Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM & Tewari HD 1988 Total androgen blockade versus castration in metastatic cancer of the prostate. In Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects, pp 302-311. Eds M Motta & M Serio. Bussum: Medicom.
3. Bostwick DG 1995 High grade prostatic intraepithelial neoplasia: the most likely precursor of prostate cancer. Cancer 75 1823-1836.
4. Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM & Soloway MS 1995 Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 75 1634-1641.
5. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 313 419-424.
6. Denis L, Carneiro de Moura JL, Bono A, Sylvester R, Wheeton R, Newling D & Pauno MD 1993 Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 119-129.
7. Hellstrom M, Haggman M, Brandstedt S, de la Torre M, Pedersen K, Jarlsfeldt I, Wijkstrom H & Busch C 1993 Histopathological changes in androgen-deprived localized prostatic cancer - a study in total prostatectomy specimens. European Urology 24 461-465.
8. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Silva FC, Knonagel H & Venner P 1993 Orchiectomy and Anandron (Nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. Journal of Urology 149 77-83.
9. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL & Emond J 1992 Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer. Journal of Urology 147 846-852.
10. Labrie F, Bélanger A, Simard J, Labrie C & Dupont A 1993a Combination therapy for prostate cancer endocrine and biological basis of its choice as new standard first line therapy. Cancer 71 1059-1067.
11. Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Emond J & Candas B 1993b Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clinical and Investigative Medicine 16 511-521.
12. Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M & Fabris G 1994 Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Journal of Clinical Pathology 47 906-913.
13. Murphy WM, Soloway MS & Barrows GH 1991 Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68 821-828.
14. Ro JY, Grignon DJ, Troncoso P & Ayala AG 1988 Intraluminal crystalloids in whole-organ sections of prostate. The Prostate 13 233-239.
15. Schmid HP & McNeal JE 1992 An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. American Journal of Surgical Pathology 16 184-191.
16. Smith DM & Murphy WM 1994 Histologic changes in prostatic carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer 73 1472-1477.
17. Têtu B, Srigley JR, Boivin JC, Dupont A, Monfette G, Pinault S & Labrie F 1991 Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. American Journal of Surgical Pathology 15 111-120.
18. Vaillancourt L, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu R, Diamond P, Candas B & Labrie F 1996 Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. American Journal of Surgical Pathology 20 86-93.
19. Van der Kwast ThH, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P & Labrie F 1996 Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. The Prostate 28 227-231.
20. Van Poppel H, Ridder D, Elgamal AA, Van de Voorde W, Werbroouck P, Ackaert K, Oyen R, Pittomvils G, Baert L & members of the Belgian Uro-oncological Study Group 1995 Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. Journal of Urology 154 429-434.